SABCS 2020 | E2112: endocrine therapy plus entinostat in HR+ advanced breast cancer

Roisin Connolly, MD, University College Cork, Cork, Ireland, discusses the results of the E2112 study, a randomized, Phase III registration trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive, advanced breast cancer. Overall survival results and progression-free survival results did not indicate a benefit of the investigational arm of the standard endocrine therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).